查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049228

肝素市場規模、佔有率、趨勢和預測：按產品、來源、給藥途徑、應用、最終用戶、分銷管道和地區分類，2026-2034年

Heparin Market Size, Share, Trends and Forecast by Product, Source, Mode of Administration, Application, End-User, Distribution Channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

2025年全球肝素市場規模為76億美元。展望未來，IMARC Group預測，2026年至2034年間，該市場將以2.03%的複合年成長率成長，到2034年達到92億美元。北美目前佔據市場主導地位，到2024年將擁有高達36%的市場佔有率。推動市場成長的主要因素包括：對有效心血管疾病治療方法的需求不斷成長、主要公司對研發的大量投入、外科手術的普及以及易患慢性疾病的老年人口顯著增加。

肝素（C12H19NO20S3）是一種廣泛使用的抗凝血劑，能夠抑制血液凝固，是多種醫療應用中不可或缺的物質。此藥物來自動物組織，用於預防靜脈、動脈和肺部血栓形成。肝素主要由硫酸多醣組成，其特性包括起效迅速以及能夠與抗凝血酶III形成複合物，從而惰性凝血酶。肝素廣泛應用於各種醫療場景，包括手術、透析以及治療深層靜脈栓塞症和肺動脈栓塞。肝素的作用機轉是促進身體本身的抗凝血反應，溶解已形成的血栓，並防止新血栓的形成。

全球市場的主要驅動力是心血管疾病有效治療方法需求的不斷成長。種類繁多且價格適中的肝素製劑的廣泛應用也促進了市場成長。此外，易患血栓性疾病的老年人口顯著增加是市場成長的關鍵促進因素。同時，需要抗凝血治療的手術和介入治療數量的增加也推高了產品需求。規範化的醫療保健體系的普及，以及對血液相關疾病的妥善管理，進一步推動了市場成長。此外，可導致凝血障礙的文明病的流行也是市場成長的促進因素。其他促進市場成長的因素包括快速的都市化、現代生活方式、人們健康管理意識的轉變以及醫療機構、製藥公司和研究機構之間的廣泛合作。

肝素市場趨勢及促進因素：

慢性病患者數量顯著增加。

在全球範圍內，心臟病、癌症和糖尿病等慢性疾病的日益流行，使得抗凝血劑（尤其是肝素）的使用備受關注。這些慢性疾病常常導致血栓和血栓症等繼發性併發症，需要使用抗凝血劑來控制和預防這些危及生命的狀況。生活方式的改變，包括久坐不動的生活方式、不良的飲食習慣以及其他因素，都加劇了這些慢性疾病的發生，從而導致對有效血栓治療的需求不斷成長。此外，醫療專業人員和機構正在推廣預防措施，包括對高風險患者使用抗凝血劑。抗凝血劑在日益流行的疾病群併發症管理中的廣泛應用，正在為市場擴張奠定基礎，並塑造著當前的醫療實踐和未來的發展趨勢。

藥物輸送系統的持續技術創新

技術創新已成為市場的關鍵要素。輸液幫浦、預填充式注射器和標靶給藥等藥物傳遞系統的進步，使得抗凝血劑的給藥更精準有效。這些創新降低了藥物過量和副作用的風險，並提高了患者的安全性和舒適度。此外，隨著醫療技術的進步，將數位監測技術應用於肝素給藥，可即時監測患者的反應，從而製定個人化的治療方案，改善治療效果。持續的研究和投資不僅提升了抗凝血劑的整體使用體驗，也增強了醫病之間的信任。科技與醫學的融合是推動市場朝著更動態、以病人為中心的方向發展的關鍵動力。

擴大監管支持和核准

市場擴張很大程度上受監管環境的影響，其中包括各類政府機構、國際組織和衛生部門。這種嚴格的監管環境確保肝素產品符合品質、安全性和有效性標準。這種監管貫穿從研發到上市後監測的各個階段。新肝素製劑和適應症的快速核准流程，以及明確的指南和支持性政策，促進了藥物的可及性和合理使用。此外，監管支持通常還包括為研究提供財政獎勵、促進政府與製藥公司之間的合作以及進行血栓性疾病的宣傳活動。透過營造兼顧安全性和創新性的環境，監管支持是支撐肝素市場強勁成長的關鍵支柱，有助於建立信任，並確保所需的患者能夠獲得最佳治療。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球肝素市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場區隔：依產品分類
  • 市場區隔：按產地
  • 市場區隔：依管理方法
  • 市場區隔：按應用領域
  • 市場區隔：依最終用戶分類
  • 市場區隔：依分銷通路分類
  • 市場區隔：按地區
  • 市場預測

第6章 市場區隔：依產品分類

  • 未分級肝素
  • 低分子量肝素（LMWH）
  • 超低分子量肝素（ULMWH）

第7章 市場區隔：依產地分類

  • 源自牛
  • 源自豬

第8章 市場區隔：依管理方法

  • 口服
  • 腸外

第9章 市場區隔：依應用領域分類

  • 心房顫動和心肌梗死
  • 中風
  • 深層靜脈栓塞症（DVT）
  • 肺動脈栓塞（PE）
  • 其他

第10章 市場區隔：依最終用戶分類

  • 醫院
  • 診所
  • 居家醫療
  • 門診手術中心
  • 其他

第11章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 零售藥房
  • 藥局
  • 網路商店
  • 其他

第12章 市場區隔：依地區分類

  • 歐洲
  • 北美洲
  • 亞太地區
  • 中東和非洲
  • 拉丁美洲

第13章 SWOT 分析

第14章：價值鏈分析

第15章：波特五力分析

第16章：價格分析

第17章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • GlaxoSmithKline Plc
    • Shenzhen Hepalink Pharmaceutical Co., Ltd
    • Pfizer Inc.
    • LEO Pharma A/S
    • Sanofi SA
    • Dr. Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Aspen Holdings
    • Baxter International Inc.
    • Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
    • Sandoz International GmbH
    • Opocrin SpA
    • Sichuan Deebio Pharmaceutical Co., Ltd.
    • Dongying Tiandong Pharmaceutical Co., Ltd.
Product Code: SR112026A1564

The global heparin market size was valued at USD 7.6 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 9.2 Billion by 2034, exhibiting a CAGR of 2.03% during 2026-2034.North America currently dominates the market, holding a significant market share of 36% in 2024. The rising need for effective treatment options for cardiovascular diseases, substantial investments in R&D activities by the key players, the growing prevalence of numerous surgical procedures, and the considerable rise in the number of geriatric population that is susceptible to chronic diseases are the key factors bolstering the market.

Heparin (C12H19NO20S3) is a widely used anticoagulant, a substance that inhibits blood clotting, making it essential in various medical applications. Sourced from animal tissues, this medication is administered to patients to prevent blood clots in veins, arteries, and lungs. Comprising mainly of sulfated polysaccharides, the properties of heparin include a rapid onset of action and the ability to form a complex with antithrombin III, which inactivates clotting enzymes. It's used in various medical situations such as during surgeries, dialysis, and in the treatment of deep vein thrombosis and pulmonary embolisms. Heparin works by enhancing the body's natural anticoagulant response, breaking down clots, and preventing the formation of new ones.

The global market is primarily driven by the increasing need for effective treatment options for cardiovascular diseases. In line with this, the widespread availability of varied and affordable heparin options is also providing an impetus to the market. Moreover, the considerable rise in the aging population, more susceptible to clotting disorders, is acting as a significant growth-inducing factor for the market. In addition to this, the growing number of surgeries and invasive procedures requiring anticoagulation therapy is resulting in higher product demand. The market is further driven by the implementation of organized healthcare systems that necessitate the proper management of blood-related conditions. Apart from this, the prevalence of lifestyle-related diseases that may lead to clotting disorders is propelling the market. Some of the other factors contributing to the market include rapid urbanization and modern lifestyles, the cultural shift towards more proactive health management, and extensive collaboration between healthcare providers, pharmaceutical companies, and research institutions.

Heparin Market Trends/Drivers:

Considerable rise in the number of chronic conditions

The global rise in chronic conditions such as heart disease, cancer, and diabetes has brought the use of anticoagulants, particularly heparin, into sharp focus. These chronic conditions often lead to secondary complications like blood clots and thrombosis, requiring the administration of anticoagulants to manage and prevent these potentially fatal occurrences. As lifestyles continue to evolve, sedentary habits, poor diet, and other factors are contributing to an increase in these chronic conditions, thereby pushing the demand for effective clot management treatments. Furthermore, healthcare practitioners and medical organizations are promoting preventive measures, including use in at-risk patients. This wide-ranging applications of this anticoagulant in managing complications from an increasingly prevalent group of diseases is serving as a cornerstone in the expansion of the market, shaping both current practices and future trends in healthcare.

Continual technological advancements in drug delivery systems

Technological innovation has become a pivotal factor in the market. The advancement in drug delivery systems, such as infusion pumps, prefilled syringes, and targeted delivery, ensures that the anticoagulant can be administered more accurately and effectively. These innovations reduce the risk of overdosage and side effects, thereby enhancing patient safety and comfort. Additionally, as medical technology evolves, the integration of digital monitoring with heparin delivery allows for real-time monitoring of patient response, enabling personalized treatment plans and greater therapeutic efficacy. The continuous research and investment in this technology not only improve the overall usage experience of anticoagulants but also foster trust among healthcare providers and patients. The convergence of technology and medicine in this aspect is a significant driving force, steering the market towards a more dynamic and patient-centric direction.

Growing regulatory support and approvals

The market expansion is significantly impacted by the regulatory landscape, encompassing various government bodies, international organizations, and healthcare authorities. The stringent regulatory environment ensures that heparin products meet quality, safety, and efficacy standards. This scrutiny extends to every stage, from the research and development phase to post-market surveillance. Rapid approval processes for new Heparin formulations and applications, alongside clear guidelines and supportive policies, help facilitate the drug's availability and proper usage. Furthermore, the regulatory support often extends to financial incentives for research, collaboration between governments and pharmaceutical companies, and public awareness campaigns about blood clot disorders. By cultivating an environment that balances safety with innovation, the regulatory support serves as a key pillar in the robust growth of the Heparin market, fostering trust, and ensuring that the best possible care reaches patients in need.

Heparin Industry Segmentation:

The publisher provides an analysis of the key trends in each segment of the global heparin market, along with forecast at the global, regional, and country levels from 2026-2034. The market has been categorized based on the product, source, mode of administration, application, end-user, and distribution channel.

Breakup by Product:

  • Unfractionated Heparin
  • Low Molecular Weight Heparin (LMWH)
  • Ultra-Low Molecular Weight Heparin (ULMWH)

Low molecular weight heparin (LMWH) represents the largest market segment

The growing preference for low molecular weight heparin (LMWH) can be attributed to its enhanced bioavailability and prolonged action compared to the unfractionated variant. LMWH offers a more predictable dose-response relationship, reducing the need for frequent monitoring and dose adjustments. Its lower risk of causing heparin-induced thrombocytopenia (HIT) contributes to its favorability in both prophylactic and therapeutic settings. Additionally, LMWH's ease of subcutaneous administration and potential for outpatient care further promote its adoption, aligning with the trend towards patient-centric healthcare.

On the other hand, the unfractionated heparin and ultra-low molecular weight heparin (ULMWH) segments of the market are driven by several factors. These factors include their clinical efficacy in preventing and treating thrombotic conditions, their diverse applications in addressing deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis, and the influence of physician preferences based on patient profiles and medical history.

Breakup by Source:

  • Bovine
  • Porcine

Porcine accounts for the majority of the market share

The utilization of porcine mucosal tissues as the primary product source is driven by the high concentration of precursors in these tissues. Porcine source remains integral to the heparin production process due to its reliability, scalability, and cost-effectiveness. However, the industry's ongoing exploration of alternative sources, driven by concerns over availability and ethical considerations, underscores the importance of diversifying raw material options to ensure a stable supply chain for this critical anticoagulant.

On the other hand, the use of heparin sourced from bovine origins has been historically prominent in medical applications due to its availability and established track record. Also, continual advances in purification processes have addressed concerns related to potential contaminants and allergenic reactions associated with bovine-sourced anticoagulants, which is impelling the segment.

Breakup by Mode of Administration:

  • Oral
  • Parenteral

Oral represents the largest market segment

The development of oral formulations for anticoagulants marks a significant advancement in patient care. The shift from injectable to oral administration stems from the desire to enhance patient compliance, reduce the burden of injections, and facilitate long-term therapy. However, the challenge lies in achieving consistent bioavailability and maintaining predictable anticoagulation effects with oral formulations. Extensive research and clinical trials are being conducted to refine oral anticoagulant drugs, aiming to strike a balance between efficacy, safety, and convenience.

On the other hand, the parenteral mode of administration, involving injections, offers immediate effects that are particularly suitable for acute situations such as stroke and thrombotic events. This mode of administration ensures predictable dosing, which enhances patient safety and treatment efficacy.

Breakup by Application:

  • Atrial Fibrillation & Heart Attack
  • Stroke
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Others

Atrial fibrillation and heart attacks account for the majority of the market share

Atrial fibrillation and heart attacks are pivotal drivers of the demand for various anticoagulants. The increased incidence of these conditions underscores the critical role of timely and effective anticoagulation in preventing thromboembolic events. Atrial fibrillation, characterized by irregular heart rhythms, necessitates ongoing anticoagulant therapy to prevent blood clot formation and potential stroke. Meanwhile, in the context of heart attacks, the product's role as an adjunctive therapy complements other interventions to prevent further clotting and optimize patient outcomes.

On the other hand, the rising prevalence of stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE) drives the demand for effective anticoagulation therapies. The aging global population contributes to a higher incidence of these conditions, emphasizing the need for suitable treatment options.

Breakup by End-User:

  • Hospitals
  • Clinics
  • Homecare Settings
  • Ambulatory Surgical Centers
  • Others

Hospitals represent the largest market segment

Hospitals serve as central hubs for patient care, where the use of heparin spans from surgical procedures to the treatment of thrombotic events for preventing blood clot formation. Hospitals' high patient throughput and critical nature of care emphasize the need for accessible and effective anticoagulation options. As healthcare facilities continue to evolve, optimizing product utilization and management within hospital protocols contributes to patient safety and overall quality of care.

On the other hand, the growing product applications across clinics, homecare settings, and ambulatory surgical centers reflects its versatility in catering to different patient care environments. This is especially convenient for patients, as it allows effective treatment in home-based or ambulatory settings.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Stores
  • Others

Hospital pharmacies account for the majority of the market share

Hospital pharmacies play a pivotal role in the anticoagulant distribution and management within healthcare institutions. Their efficient procurement, storage, and dispensing of pharmaceuticals impact the product availability for clinicians. Additionally, hospital pharmacies facilitate communication between healthcare providers and manufacturers, ensuring timely restocking and adherence to quality standards. An effectively managed distribution channel contributes to seamless patient care and supports hospital staff in delivering appropriate therapies in a timely manner.

On the other hand, the easy product accessibility in retail pharmacies, drug stores, and online stores ensures wider patient access to necessary anticoagulant medications. This availability caters to diverse consumer preferences, allowing some patients to conveniently obtain anticoagulants from their preferred retail or online sources.

Breakup by Region:

  • Europe
  • North America
  • Asia Pacific
  • Middle East and Africa
  • Latin America

North America exhibits a clear dominance, accounting for the largest heparin market share

The report has also provided a comprehensive analysis of all the major regional markets, which include Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share.

The market in the North America region is propelled by the region's high incidence of chronic diseases, notably cardiovascular disorders, deep vein thrombosis, and pulmonary embolism, fuels the demand for heparin as a vital anticoagulant and thromboprophylactic agent.

This demand is further magnified by the increasing proportion of the aging population, a demographic more prone to conditions necessitating anticoagulant treatment. The region's advanced healthcare infrastructure, coupled with the burgeoning number of surgical procedures, including cardiovascular surgeries and orthopedic interventions, fosters a significant need for heparin-based products to mitigate blood clot formation risks.

Improved awareness of thrombotic disorders and enhanced diagnostic techniques contribute to early detection and treatment, amplifying the necessity for product interventions. The stringent regulatory landscape in North America ensures the secure and effective utilization of anticoagulant drugs, including heparin, while ongoing research, collaborative endeavors, and innovations in the field continually refine product efficacy and safety profile. In summation, a dynamic interplay of demographic trends, healthcare infrastructure, medical awareness, regulatory standards, and research advancements collectively stimulate the rising demand for anticoagulant products across various medical domains.

Competitive Landscape:

The leading market players are investing significantly in R&D to develop improved formulations and delivery methods, enhancing the effectiveness and safety of heparin products. These efforts aim to address medical needs more efficiently and reduce potential side effects. To tap into new markets and diversify revenue streams, major manufacturers are expanding their geographic presence by establishing distribution networks, manufacturing facilities, and sales operations in emerging markets. Additionally, they are investing in advanced quality control measures, adherence to Good Manufacturing Practices (GMP), and transparency in their supply chains to maintain customer trust and regulatory approval. The key players are also forming strategic partnerships with research institutions, healthcare providers, and pharmaceutical companies to collectively advance heparin-based treatments.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided.

Some of the key players in the market include:

  • GlaxoSmithKline Plc
  • Shenzhen Hepalink Pharmaceutical Co., Ltd
  • Pfizer Inc.
  • LEO Pharma A/S
  • Sanofi S.A.
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Aspen Holdings
  • Baxter International Inc.
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
  • Sandoz International GmbH
  • Opocrin S.p.A.
  • Sichuan Deebio Pharmaceutical Co., Ltd.
  • Dongying Tiandong Pharmaceutical Co. Ltd.

Key Questions Answered in This Report

  • How big is the heparin market?
  • What is the future outlook of the heparin market?
  • What are the key factors driving the heparin market?
  • Which region accounts for the largest heparin market share?
  • Which are the leading companies in the global heparin market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Heparin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Product
  • 5.5 Market Breakup by Source
  • 5.6 Market Breakup by Mode of Administration
  • 5.7 Market Breakup by Application
  • 5.8 Market Breakup by End-User
  • 5.9 Market Breakup by Distribution Channel
  • 5.10 Market Breakup by Region
  • 5.11 Market Forecast

6 Market Breakup by Product

  • 6.1 Unfractionated Heparin
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Low Molecular Weight Heparin (LMWH)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Ultra-Low Molecular Weight Heparin (ULMWH)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Source

  • 7.1 Bovine
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Porcine
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Mode of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Parenteral
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Atrial Fibrillation & Heart Attack
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Stroke
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Deep Vein Thrombosis (DVT)
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Pulmonary Embolism (PE)
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by End-User

  • 10.1 Hospitals
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Clinics
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Homecare Settings
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Ambulatory Surgical Centers
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Others
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 Market Breakup by Distribution Channel

  • 11.1 Hospital Pharmacies
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Retail Pharmacies
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 Drug Stores
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast
  • 11.4 Online Stores
    • 11.4.1 Market Trends
    • 11.4.2 Market Forecast
  • 11.5 Others
    • 11.5.1 Market Trends
    • 11.5.2 Market Forecast

12 Market Breakup by Region

  • 12.1 Europe
    • 12.1.1 Market Trends
    • 12.1.2 Market Forecast
  • 12.2 North America
    • 12.2.1 Market Trends
    • 12.2.2 Market Forecast
  • 12.3 Asia Pacific
    • 12.3.1 Market Trends
    • 12.3.2 Market Forecast
  • 12.4 Middle East and Africa
    • 12.4.1 Market Trends
    • 12.4.2 Market Forecast
  • 12.5 Latin America
    • 12.5.1 Market Trends
    • 12.5.2 Market Forecast

13 SWOT Analysis

  • 13.1 Overview
  • 13.2 Strengths
  • 13.3 Weaknesses
  • 13.4 Opportunities
  • 13.5 Threats

14 Value Chain Analysis

15 Porter's Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

  • 17.1 Market Structure
  • 17.2 Key Players
  • 17.3 Profiles of Key Players
    • 17.3.1 GlaxoSmithKline Plc
    • 17.3.2 Shenzhen Hepalink Pharmaceutical Co., Ltd
    • 17.3.3 Pfizer Inc.
    • 17.3.4 LEO Pharma A/S
    • 17.3.5 Sanofi S.A.
    • 17.3.6 Dr. Reddy's Laboratories Ltd.
    • 17.3.7 Teva Pharmaceutical Industries Ltd.
    • 17.3.8 Aspen Holdings
    • 17.3.9 Baxter International Inc.
    • 17.3.10 Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
    • 17.3.11 Sandoz International GmbH
    • 17.3.12 Opocrin S.p.A.
    • 17.3.13 Sichuan Deebio Pharmaceutical Co., Ltd.
    • 17.3.14 Dongying Tiandong Pharmaceutical Co., Ltd.

List of Figures

  • Figure 1: Global: Heparin Market: Major Drivers and Challenges
  • Figure 2: Global: Heparin Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Heparin Market: Breakup by Product (in %), 2025
  • Figure 4: Global: Heparin Market: Breakup by Source (in %), 2025
  • Figure 5: Global: Heparin Market: Breakup by Mode of Administration (in %), 2025
  • Figure 6: Global: Heparin Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Heparin Market: Breakup by End-User (in %), 2025
  • Figure 8: Global: Heparin Market: Breakup by Distribution Channel (in %), 2025
  • Figure 9: Global: Heparin Market: Breakup by Region (in %), 2025
  • Figure 10: Global: Heparin Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 11: Global: Heparin Industry: SWOT Analysis
  • Figure 12: Global: Heparin Industry: Value Chain Analysis
  • Figure 13: Global: Heparin Industry: Porter's Five Forces Analysis
  • Figure 14: Global: Heparin (Unfractionated) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Heparin (Unfractionated) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Heparin (Low Molecular Weight) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Heparin (Low Molecular Weight) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Heparin (Ultra-Low Molecular Weight) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Heparin (Ultra-Low Molecular Weight) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Heparin (Bovine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Heparin (Bovine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Heparin (Porcine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Heparin (Porcine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Heparin (Oral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Heparin (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Heparin (Parenteral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Heparin (Parenteral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Heparin (Atrial Fibrillation & Heart Attack) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Heparin (Atrial Fibrillation & Heart Attack) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Heparin (Stroke) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Heparin (Stroke) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Heparin (Deep Vein Thrombosis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Heparin (Deep Vein Thrombosis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Heparin (Pulmonary Embolism) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Heparin (Pulmonary Embolism) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Heparin (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Heparin (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Heparin (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Heparin (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Global: Heparin (Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Global: Heparin (Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Global: Heparin (Homecare Settings) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Global: Heparin (Homecare Settings) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Global: Heparin (Ambulatory Surgical Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Global: Heparin (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Global: Heparin (Other End-Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Global: Heparin (Other End-Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Global: Heparin Market: Sales through Hospital Pharmacies (in Million USD), 2020 & 2025
  • Figure 49: Global: Heparin Market Forecast: Sales through Hospital Pharmacies (in Million USD), 2026-2034
  • Figure 50: Global: Heparin Market: Sales through Retail Pharmacies (in Million USD), 2020 & 2025
  • Figure 51: Global: Heparin Market Forecast: Sales through Retail Pharmacies (in Million USD), 2026-2034
  • Figure 52: Global: Heparin Market: Sales through Drug Stores (in Million USD), 2020 & 2025
  • Figure 53: Global: Heparin Market Forecast: Sales through Drug Stores (in Million USD), 2026-2034
  • Figure 54: Global: Heparin Market: Sales through Online Stores (in Million USD), 2020 & 2025
  • Figure 55: Global: Heparin Market Forecast: Sales through Online Stores (in Million USD), 2026-2034
  • Figure 56: Global: Heparin Market: Sales through Other Distribution Channels (in Million USD), 2020 & 2025
  • Figure 57: Global: Heparin Market Forecast: Sales through Other Distribution Channels (in Million USD), 2026-2034
  • Figure 58: Europe: Heparin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Europe: Heparin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: North America: Heparin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: North America: Heparin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Asia Pacific: Heparin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Asia Pacific: Heparin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Middle East and Africa: Heparin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Middle East and Africa: Heparin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Latin America: Heparin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Latin America: Heparin Market Forecast: Sales Value (in Million USD), 2026-2034

List of Tables

  • Table 1: Global: Heparin Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Heparin Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 3: Global: Heparin Market Forecast: Breakup by Source (in Million USD), 2026-2034
  • Table 4: Global: Heparin Market Forecast: Breakup by Mode of Administration (in Million USD), 2026-2034
  • Table 5: Global: Heparin Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 6: Global: Heparin Market Forecast: Breakup by End-User (in Million USD), 2026-2034
  • Table 7: Global: Heparin Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 8: Global: Heparin Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 9: Global: Heparin Market Structure
  • Table 10: Global: Heparin Market: Key Players